bioMérieux is a global leader in microbiology and infectious disease diagnostics, providing comprehensive diagnostic solutions to improve patient health and ensure consumer safety. The company has integrated the BioFire product line into its portfolio, offering a wider range of solutions and technologies to address pressing healthcare issues.

BioFire Diagnostics, LLC

bioMérieux

With more than 25 years of molecular experience, BioFire Diagnostics, LLC (now bioMérieux) sets the standard for molecular diagnostics through its pioneering advances in syndromic infectious disease testing. As BioMérieux’s Global Center of Excellence for Molecular Diagnostics, no other company has FDA-cleared and CE-IVD marked assays for more pathogens. BioFire Diagnostics has produced the easiest, fastest, and most comprehensive multiplex PCR testing available: the BioFire® FilmArray® System.

The FDA-cleared BioFire System panels test for viruses, bacteria, parasites, yeast, and antimicrobial resistance genes. Whether you’re trying to determine optimal therapy for a septic patient or pinpoint which respiratory pathogen is making a young child sick, the BioFire System can provide definitive answers—fast.

The BioFire brand is evolving and there are some changes we’re excited to show you. bioMérieux, a global presence and world leader in infectious disease diagnostics, acquired BioFire in 2014 and it’s time to align our two companies. In January 2022, the BioFire product line will be folded into the bioMérieux product portfolio. As a company, it will simply be called bioMérieux. Read our newest blog post to see what the future holds for this amazing company. #WeArebioMerieux #NewBeginnings https://bit.ly/3o01mfV

COM:BIOFIREDX

bioMérieux

locale

market

industry

website

crunchbase

linkedin

Issues Detected

peer of

Metrics